Page last updated: 2024-10-26

diclofenac and Hypertension

diclofenac has been researched along with Hypertension in 47 studies

Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.

Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.

Research Excerpts

ExcerptRelevanceReference
"A 4-week, multicentre, randomised, double-blind study has compared the effects of lumiracoxib 100 mg once daily (od) (n = 394) and ibuprofen 600 mg three times daily (tid) (n = 393) on ambulatory BP in osteoarthritis (OA) patients with controlled hypertension."9.14The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. ( Krammer, G; Lheritier, K; MacDonald, TM; Richard, D, 2010)
"In senior salt-sensitive patients with hypertension, coadministration of misoprostol with diclofenac attenuated the blood pressure elevation and renal vasoconstrictive effects of diclofenac and was well tolerated."9.13Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study. ( Ateshkadi, A; Barri, YM; Cheung, AK; Gardner, SF; Munger, MA; Rabetoy, GM; Stoddard, GJ, 2008)
"Treatment with lumiracoxib 100 mg once daily resulted in clinically significant lower blood pressure compared with ibuprofen 600 mg three times daily in osteoarthritis patients with well controlled hypertension."9.13Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. ( Krammer, G; Lheritier, K; Littlejohn, TW; MacDonald, TM; Rebuli, R; Reginster, JY; Richard, D, 2008)
"This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis."9.10Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. ( Carter, R; Evans, S; Imrie, C; Murray, B; O'Suilleabhain, C, 2003)
"A placebo-controlled, double blind crossover study of the non-steroidal anti-inflammatory drugs (NSAIDs) sulindac and diclofenac was conducted in 16 patients with essential hypertension that was controlled by treatment with a beta blocker, a diuretic or co-administration of both."9.07The effects of sulindac and diclofenac in essential hypertension controlled by treatment with a beta blocker and/or diuretic. ( Brooks, PM; Johnston, HJ; Kelly, D; Monaghan, JC; Okoro, EO; Stokes, GS, 1991)
"Celecoxib significantly increased the incidence of new onset hypertension in this cohort of Indian patients with rheumatic diseases."7.79How safe is Celecoxib for Asian-Indian patients with rheumatic diseases? ( Chandra, C; Chandy, SJ; Danda, D; Iliyas, MM; Mathew, AJ, 2013)
"The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12."7.71A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002)
"Since the effects of angiotensin II receptor antagonism on arterial function in nitric oxide (NO)-deficient hypertension are unknown, we investigated the influence of losartan therapy (20 mg kg-1 day-1) on the control of arterial tone in NG-nitro-L-arginine methyl ester (L-NAME; 20 mg kg-1 day-1)-induced hypertension."7.70Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism. ( Holm, P; Hutri-Kähönen, N; Jolma, P; Kähönen, M; Kalliovalkama, J; Pörsti, I; Tolvanen, JP; Wu, X, 1999)
" The improved endothelium-mediated relaxation following ramipril therapy could be attributed to reduced release of cyclo-oxygenase-derived constricting factors and augmented endothelium-dependent hyperpolarization in this type of experimental hypertension."7.69Ramipril therapy improves arterial dilation in experimental hypertension. ( Hutri-Kähönen, N; Kähönen, M; Pörsti, I; Sallinen, K; Tolvanen, JP; Wu, X, 1997)
"Post-screening and on inclusion, patients were put on a 2-week washout period and then randomly assigned to either only lisinopril 10 mg or combination of lisinopril 10 mg and diclofenac sodium 100 mg treatments for 8-12 weeks in diseased states of hypertension and osteoarthritis with or without type 2 diabetes mellitus."5.15Potential pharmacodynamic drug-drug interaction between concomitantly administered lisinopril and diclofenac sodium: a call for appropriate management in hypertensive osteoarthritic patients. ( Chudasama, H; Goswami, SK; Jain, S; Santani, D, 2011)
"To evaluate the hypertensive effects of etoricoxib and diclofenac relative to baseline hypertension risk factors in arthritis patients."5.14Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. ( Brater, DC; Cannon, CP; Curtis, SP; Kaur, A; Krum, H; Laine, L; Smugar, SS; Swergold, G; Wang, H; Weir, MR, 2009)
"A 4-week, multicentre, randomised, double-blind study has compared the effects of lumiracoxib 100 mg once daily (od) (n = 394) and ibuprofen 600 mg three times daily (tid) (n = 393) on ambulatory BP in osteoarthritis (OA) patients with controlled hypertension."5.14The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. ( Krammer, G; Lheritier, K; MacDonald, TM; Richard, D, 2010)
"In senior salt-sensitive patients with hypertension, coadministration of misoprostol with diclofenac attenuated the blood pressure elevation and renal vasoconstrictive effects of diclofenac and was well tolerated."5.13Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study. ( Ateshkadi, A; Barri, YM; Cheung, AK; Gardner, SF; Munger, MA; Rabetoy, GM; Stoddard, GJ, 2008)
"Treatment with lumiracoxib 100 mg once daily resulted in clinically significant lower blood pressure compared with ibuprofen 600 mg three times daily in osteoarthritis patients with well controlled hypertension."5.13Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. ( Krammer, G; Lheritier, K; Littlejohn, TW; MacDonald, TM; Rebuli, R; Reginster, JY; Richard, D, 2008)
" In the first few weeks of treatment, the mean changes in some variables (VAS, which assessed walking pain, standing pain and stiffness, as well as Lequesne's functional index) of the DJW group were significantly lower than those of the diclofenac group."5.11Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892]. ( Kunanusorn, P; Lhieochaiphunt, S; Pojchamarnwiputh, S; Pruksakorn, S; Rojanasthien, N; Sananpanich, K; Teekachunhatean, S, 2004)
"This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis."5.10Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. ( Carter, R; Evans, S; Imrie, C; Murray, B; O'Suilleabhain, C, 2003)
"Fifteen women with arthritis and hypertension who were receiving lisinopril and HCT, and administered sequentially in random order ibuprofen, sulindac, and diclofenac for one month each, with an intervening two-week washout period between each treatment period."5.09Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics. ( Bhagat, K, 2001)
"A placebo-controlled, double blind crossover study of the non-steroidal anti-inflammatory drugs (NSAIDs) sulindac and diclofenac was conducted in 16 patients with essential hypertension that was controlled by treatment with a beta blocker, a diuretic or co-administration of both."5.07The effects of sulindac and diclofenac in essential hypertension controlled by treatment with a beta blocker and/or diuretic. ( Brooks, PM; Johnston, HJ; Kelly, D; Monaghan, JC; Okoro, EO; Stokes, GS, 1991)
" The study was based on a randomized, crossover design to compare the effect of an NSAID, sulindac, with that of another NSAID, diclofenac sodium, in the hypertension treatment."5.07No adverse effect of non-steroidal anti-inflammatory drugs, sulindac and diclofenac sodium, on blood pressure control with a calcium antagonist, nifedipine, in elderly hypertensive patients. ( Abe, K; Sato, K; Sato, M; Takeuchi, K; Tanno, M; Yasujima, M; Yoshinaga, K, 1991)
"In an open triple crossover study in 8 patients with essential hypertension, the possibility has been investigated of whether the blood pressure lowering effect of hydrochlorothiazide 50 mg once daily was attenuated by co-administration for 4 weeks of ibuprofen 400 mg t."5.06The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. ( Gribnau, FW; Koopmans, PP; Thien, T, 1987)
" Two female and two male patients with essential hypertension were given dihydralazine plus saline or dihydralazine plus diclofenac intravenously on two separate occasions."5.05Are prostaglandins involved in the antihypertensive effect of dihydralazine? ( Frölich, JC; Ratge, D; Reimann, IW; Wisser, H, 1981)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."4.21 ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
"Celecoxib significantly increased the incidence of new onset hypertension in this cohort of Indian patients with rheumatic diseases."3.79How safe is Celecoxib for Asian-Indian patients with rheumatic diseases? ( Chandra, C; Chandy, SJ; Danda, D; Iliyas, MM; Mathew, AJ, 2013)
"This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease."3.77Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011)
"In view of the ongoing controversy of cardiorenal safety of selective COX-2 inhibitors (coxibs), the present study was designed to examine the effects of 2 different coxibs, celecoxib and rofecoxib, compared with a traditional NSAID, diclofenac, and placebo on renal morphology and function in salt-sensitive hypertension."3.73Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. ( Bühler, N; Camici, G; Chenevard, R; Gröne, HJ; Hermann, M; Kiss, E; Lüscher, TF; Ruschitzka, F; Shaw, S, 2005)
"These data show that celecoxib but not rofecoxib or diclofenac improves endothelial dysfunction and reduces oxidative stress, thus pointing to differential effects of coxibs in salt-induced hypertension."3.72Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. ( Camici, G; Fiedler, M; Fratton, A; Gay, RE; Gay, S; Hellermann, JP; Hermann, M; Hurlimann, D; Lüscher, TF; Neidhart, M; Ruschitzka, F; Tanner, FC; Thiery, J, 2003)
"The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12."3.71A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002)
"Since the effects of angiotensin II receptor antagonism on arterial function in nitric oxide (NO)-deficient hypertension are unknown, we investigated the influence of losartan therapy (20 mg kg-1 day-1) on the control of arterial tone in NG-nitro-L-arginine methyl ester (L-NAME; 20 mg kg-1 day-1)-induced hypertension."3.70Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism. ( Holm, P; Hutri-Kähönen, N; Jolma, P; Kähönen, M; Kalliovalkama, J; Pörsti, I; Tolvanen, JP; Wu, X, 1999)
" The improved endothelium-mediated relaxation following ramipril therapy could be attributed to reduced release of cyclo-oxygenase-derived constricting factors and augmented endothelium-dependent hyperpolarization in this type of experimental hypertension."3.69Ramipril therapy improves arterial dilation in experimental hypertension. ( Hutri-Kähönen, N; Kähönen, M; Pörsti, I; Sallinen, K; Tolvanen, JP; Wu, X, 1997)
" Differences observed in blood pressure response between COX inhibitors may not be related in their sensitivity but rather their dosing frequency."2.71Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. ( Alausa, T; Bakris, GL; Folker, A; Hung, E; Izhar, M, 2004)
"Losartan has an antimigratory effect, reducing leukocyte migration by reducing ICAM-1 and P-selectin expression."1.33Losartan attenuates the antimigratory effect of diclofenac in spontaneously hypertensive rats. ( Carvalho, MH; Cruz, JW; Fortes, ZB; Martinez, LL; Miguel, AS; Nigro, D; Oliveira, MA; Rastelli, VM; Tostes, RC, 2005)
"Essential hypertension is associated with several alterations in arterial function."1.33Increased wall tension in response to vasoconstrictors in isolated mesenteric arterial rings from patients with high blood pressure. ( Kähönen, M; Kööbi, P; Mäki-Jouppi, J; Mustonen, J; Nordback, I; Pörsti, I; Sand, J; Tahvanainen, A; Taurio, J, 2006)

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-19904 (8.51)18.7374
1990's11 (23.40)18.2507
2000's20 (42.55)29.6817
2010's10 (21.28)24.3611
2020's2 (4.26)2.80

Authors

AuthorsStudies
Murtadha Al-Shehristani, RM1
Aziz, ND1
Nese, M1
Riboli, G1
Brighetti, G1
Sassi, V1
Camela, E1
Caselli, G1
Sassaroli, S1
Borlimi, R1
Aucoin, M1
Cooley, K1
Saunders, PR1
Carè, J1
Anheyer, D1
Medina, DN1
Cardozo, V1
Remy, D1
Hannan, N1
Garber, A1
Velayos, M1
Muñoz-Serrano, AJ1
Estefanía-Fernández, K1
Sarmiento Caldas, MC1
Moratilla Lapeña, L1
López-Santamaría, M1
López-Gutiérrez, JC1
Li, J2
Zhang, J4
Shen, S1
Zhang, B3
Yu, WW1
Toyoda, H1
Huang, DQ1
Le, MH1
Nguyen, MH1
Huang, R1
Zhu, L1
Wang, J6
Xue, L1
Liu, L2
Yan, X2
Huang, S3
Li, Y6
Xu, T1
Li, C2
Ji, F1
Ming, F1
Zhao, Y2
Cheng, J1
Wang, Y3
Zhao, H2
Hong, S1
Chen, K2
Zhao, XA1
Zou, L1
Sang, D1
Shao, H1
Guan, X1
Chen, X2
Chen, Y5
Wei, J1
Zhu, C1
Wu, C1
Moore, HB1
Barrett, CD1
Moore, EE1
Jhunjhunwala, R1
McIntyre, RC1
Moore, PK1
Hajizadeh, N1
Talmor, DS1
Sauaia, A1
Yaffe, MB1
Liu, C3
Lin, Y1
Dong, Y1
Wu, Y1
Bao, Y1
Yan, H2
Ma, J1
Fernández-Cuadros, ME1
Albaladejo-Florín, MJ1
Álava-Rabasa, S1
Usandizaga-Elio, I1
Martinez-Quintanilla Jimenez, D1
Peña-Lora, D1
Neira-Borrajo, I1
López-Muñoz, MJ1
Rodríguez-de-Cía, J1
Pérez-Moro, OS1
Abdallah, M1
Alsaleh, H1
Baradwan, A1
Alfawares, R1
Alobaid, A1
Rasheed, A1
Soliman, I1
Wendel Garcia, PD1
Fumeaux, T1
Guerci, P1
Heuberger, DM1
Montomoli, J2
Roche-Campo, F1
Schuepbach, RA1
Hilty, MP1
Poloni, TE1
Carlos, AF1
Cairati, M1
Cutaia, C1
Medici, V1
Marelli, E1
Ferrari, D1
Galli, A1
Bognetti, P1
Davin, A1
Cirrincione, A1
Ceretti, A1
Cereda, C1
Ceroni, M1
Tronconi, L1
Vitali, S1
Guaita, A1
Leeds, JS1
Raviprakash, V1
Jacques, T1
Scanlon, N1
Cundall, J1
Leeds, CM1
Riva, A1
Gray, EH1
Azarian, S1
Zamalloa, A1
McPhail, MJW1
Vincent, RP1
Williams, R1
Chokshi, S1
Patel, VC1
Edwards, LA1
Alqarawi, W1
Birnie, DH1
Golian, M1
Nair, GM1
Nery, PB1
Klein, A1
Davis, DR1
Sadek, MM1
Neilipovitz, D1
Johnson, CB1
Green, MS1
Redpath, C1
Miller, DC1
Beamer, P1
Billheimer, D1
Subbian, V1
Sorooshian, A1
Campbell, BS1
Mosier, JM1
Novaretti, JV1
Astur, DC1
Cavalcante, ELB1
Kaleka, CC1
Amaro, JT1
Cohen, M1
Huang, W1
Li, T1
Ling, Y1
Qian, ZP1
Zhang, YY1
Huang, D1
Xu, SB1
Liu, XH1
Xia, L1
Yang, Y5
Lu, SH1
Lu, HZ1
Zhang, R2
Ma, JX1
Tang, S1
Li, CM1
Wan, J1
Wang, JF1
Ma, JQ1
Luo, JJ1
Chen, HY2
Mi, SL1
Chen, SY1
Su, YG1
Ge, JB1
Milheiro, SA1
Gonçalves, J1
Lopes, RMRM1
Madureira, M1
Lobo, L1
Lopes, A1
Nogueira, F1
Fontinha, D1
Prudêncio, M1
M Piedade, MF1
Pinto, SN1
Florindo, PR1
Moreira, R1
Castillo-Lora, J1
Delley, MF1
Laga, SM1
Mayer, JM1
Sutjarit, N1
Thongon, N1
Weerachayaphorn, J1
Piyachaturawat, P1
Suksamrarn, A1
Suksen, K1
Papachristou, DJ1
Blair, HC1
Hu, Y2
Shen, P1
Zeng, N1
Wang, L5
Yan, D1
Cui, L1
Yang, K2
Zhai, C1
Yang, M1
Lao, X1
Sun, J2
Ma, N1
Wang, S1
Ye, W1
Guo, P1
Rahimi, S1
Singh, MP1
Gupta, J1
Nakanishi, I1
Ohkubo, K1
Shoji, Y1
Fujitaka, Y1
Shimoda, K1
Matsumoto, KI1
Fukuhara, K1
Hamada, H1
van der Boom, T1
Gruppen, EG1
Lefrandt, JD1
Connelly, MA1
Links, TP1
Dullaart, RPF1
Berry, JD1
Bedlack, R1
Mathews, D1
Agnese, W1
Apple, S1
Meloncelli, S1
Divizia, M1
Germani, G1
Adefegha, SA1
Bottari, NB1
Leal, DB1
de Andrade, CM1
Schetinger, MR1
Martínez-Velasco, A1
Perez-Ortiz, AC1
Antonio-Aguirre, B1
Martínez-Villaseñor, L1
Lira-Romero, E1
Palacio-Pastrana, C1
Zenteno, JC1
Ramirez, I1
Zepeda-Palacio, C1
Mendoza-Velásquez, C1
Camacho-Ordóñez, A1
Ortiz Bibriesca, DM1
Estrada-Mena, FJ1
Martin, BL1
Thompson, LC1
Kim, YH2
Snow, SJ1
Schladweiler, MC1
Phillips, P1
Harmon, M1
King, C1
Richards, J1
George, I1
Haykal-Coates, N1
Gilmour, MI1
Kodavanti, UP1
Hazari, MS1
Farraj, AK1
Shen, Z1
Zou, Y1
Gao, K1
Lazar, S1
Wurtzel, JGT1
Ma, P1
Goldfinger, LE1
Vukelic, M1
Laloo, A1
Kyttaris, VC1
Chen, R1
Chen, J2
Xun, J1
Hu, Z1
Huang, Q2
Steinhart, C1
Shen, Y1
Lu, H1
Mansuri, A1
Lokhande, K1
Kore, S1
Gaikwad, S1
Nawani, N1
Swamy, KV1
Junnarkar, M1
Pawar, S1
Shaheen, MY1
Basudan, AM1
Niazy, AA1
van den Beucken, JJJP1
Jansen, JA1
Alghamdi, HS1
Gao, Q2
Guo, X1
Cao, Y1
Jia, X1
Xu, S1
Lu, C2
Zhu, H2
Melku, M1
Abebe, G1
Teketel, A1
Asrie, F1
Yalew, A1
Biadgo, B1
Kassa, E1
Damtie, D1
Anlay, DZ1
Ahmed, MFE1
Ramadan, H1
Seinige, D1
Kehrenberg, C1
Abd El-Wahab, A1
Volkmann, N1
Kemper, N1
Schulz, J1
Hu, MY1
Wu, YN1
McEvoy, MP1
Wang, YF1
Cong, WL1
Liu, LP1
Li, XX1
Zhou, CL1
Chen, WM1
Wei, KL1
Tung, SY1
Shen, CH1
Chang, TS1
Yen, CW1
Hsieh, YY1
Chiu, WN1
Hu, JH1
Lu, SN1
Hung, CH1
Alakavuklar, MA1
Fuqua, C1
Luo, KL1
Underwood, RS1
Greenwald, I1
Elashiry, MM1
Elashiry, M1
Zeitoun, R1
Elsayed, R1
Tian, F1
Saber, SE1
Elashry, SH1
Tay, FR1
Cutler, CW1
O'Dowd, A1
Maciel, M1
Poole, ST1
Jobling, MG1
Rollenhagen, JE1
Woods, CM1
Sincock, SA1
McVeigh, AL1
Gregory, MJ1
Maves, RC1
Prouty, MG1
Holmes, RK1
Savarino, SJ1
Mor, MK1
Palevsky, PM1
Kaufman, JS1
Thiessen Philbrook, H1
Weisbord, SD1
Parikh, CR1
John, CM1
Phillips, NJ1
Jarvis, GA1
Zhu, Y1
Kilburn, S1
Kapoor, M1
Chaturvedi, S1
Shaw, KJ1
Chaturvedi, V1
Kong, X1
Zhang, T1
Xiao, H1
Feng, X1
Tu, H1
Feng, J1
Sabet, M1
Tarazi, Z1
Griffith, DC1
Nguyen, F1
Guan, P1
Guerrero, DT1
Kolla, V1
Naraparaju, K1
Perry, LM1
Soberman, D1
Pressly, BB1
Alferiev, IS1
Chorny, M1
Brodeur, GM1
Gao, X3
Cheng, YH1
Enten, GA1
DeSantis, AJ1
Gaponenko, V1
Majetschak, M1
Kim, DY1
Choi, MJ1
Ko, TK1
Lee, NH1
Kim, OH1
Cheon, HG1
Cai, H1
Yip, V1
Lee, MV1
Wong, S1
Saad, O1
Ma, S1
Ljumanovic, N1
Khojasteh, SC1
Kamath, AV1
Shen, BQ1
Cuypers, ML1
Chanteux, H1
Gillent, E1
Bonnaillie, P1
Saunders, K1
Beckers, C1
Delatour, C1
Dell'Aiera, S1
Ungell, AL1
Nicolaï, J1
Knapp, AK1
Chen, A1
Griffin-Nolan, RJ1
Baur, LE1
Carroll, CJW1
Gray, JE1
Hoffman, AM1
Li, X4
Post, AK1
Slette, IJ1
Collins, SL1
Luo, Y1
Smith, MD1
Temitayo, GI1
Olawande, B1
Emmanuel, YO1
Timothy, AT1
Kehinde, O1
Susan, LF1
Ezra, L1
Joseph, OO1
Lev, S1
Desmarini, D1
Liuwantara, D1
Sorrell, TC1
Hawthorne, WJ1
Djordjevic, JT1
Verso, MG1
Costantino, C1
Marrella, A1
Immordino, P1
Vitale, F1
Amodio, E1
Wang, YD1
Yao, WL1
Xin, ZM1
Han, TT1
Wang, ZG1
Chen, L1
Cai, C1
Zhang, Y6
Ba, D1
Wen, S1
Tian, Q1
Lv, W1
Cheng, G1
Li, N1
Yue, XY1
Chu, WJ1
Chen, Q2
Choi, ES1
Zhao, X3
Zhou, HD1
Sun, XF1
Sharma, S2
Chhoker, S1
Xie, C1
Ong, EWY1
Tan, ZK1
Evans, S2
Weinheimer, CJ1
Kovacs, A1
Williams, JW1
Randolph, GJ1
Jiang, W1
Barger, PM1
Mann, DL1
Liu, J2
Huang, Y1
Kong, L1
Yu, X1
Feng, B1
Liu, D1
Zhao, B1
Mendes, GC1
Yuan, P1
Ge, D1
Wang, WM1
Fontes, EPB1
Li, P1
Shan, L1
He, P1
Katoh, T1
Sengoku, T1
Hirata, K1
Ogata, K1
Suga, H1
Shun, C1
Yong-Yi, J1
Mei-Li, C1
Shi-Li, L1
Jian-Bo, Z1
Dan-Li, W1
Zhi-Min, G1
Ibrahim, AM1
Zakhary, SY1
Amin, SAW1
Ugurlu, M1
Fornari, VJ1
Hartmann, MSM1
Vanni, JR1
Rodriguez, R1
Langaro, MC1
Pelepenko, LE1
Zaia, AA1
Nakanjako, D1
Zalwango, F1
Wairagala, P1
Luboga, F1
Andia Biraro, I1
Bukirwa, VD1
Mboowa, MG1
Cose, S1
Seeley, J1
Elliott, A1
Zhao, G1
Sun, P1
Hao, S1
Wang, X1
Qu, G1
Xing, Y1
Xu, X1
Maierhofer, M1
Rieger, V1
Mayr, T1
Liu, Y3
Zhang, Q1
Bigliardi, AP1
Fernandes, CLF1
Pinto, EA1
Dos Santos, M1
Garcia, EM1
Baisch, PRM1
Soares, MCF1
Muccillo-Baisch, AL1
da Silva Júnior, FMR1
Yu, W1
Ju, C1
Wang, K2
Zheng, Z1
Liu, H1
Gao, Y1
Martínez-Navarro, EM1
Cebrián-Tarancón, C1
Moratalla-López, N1
Lorenzo, C1
Alonso, GL1
Salinas, RM1
Bermúdez de Castro, JM1
Modesto-Mata, M1
Martín-Francés, L1
García-Campos, C1
Martínez de Pinillos, M1
Martinón-Torres, M1
Hasani, M1
Wu, F2
Warriner, K1
Kurz, M1
Gretzke, D1
Hörlein, R1
Turpault, S1
Atzrodt, J1
Derdau, V1
Yao, Y1
Ou, X1
Zhao, S1
Tian, B1
Jin, S1
Jiang, Z1
Zhou, Z1
Liu, M2
Jiang, GD1
Mou, LH1
Chen, JJ1
Li, ZY1
He, SG1
Reale, E1
Fustinoni, S1
Mercadante, R1
Polledri, E1
Hopf, NB1
Grant, PC1
Levy, K1
Lattimer, TA1
Depner, RM1
Kerr, CW1
Sato, J1
Merenda, MEZ1
Uemoto, AT1
Dos Santos, MP1
Barion, MRL1
Carciofi, AC1
de Paula Dorigam, JC1
Ribeiro, LB1
Vasconcellos, RS1
Waller, SB1
Peter, CM1
Hoffmann, JF1
Cleff, MB1
Faria de, RO1
Zani, JL1
Martins, BA1
Sande, D1
Solares, MD1
Takahashi, JA1
Yang, S2
Jia, Y1
Yin, C1
Zhao, R1
Ojha, M1
Wu, B1
Deepa, M1
Mo, J1
Au, DW1
Wan, MT1
Shi, J1
Zhang, G1
Winkler, C1
Kong, RY1
Seemann, F1
Bianco, M1
Calvano, CD1
Ventura, G1
Bianco, G1
Losito, I1
Cataldi, TRI1
Angiolella, L1
Staudt, A1
Duarte, PF1
Amaral, BPD1
Peixoto Andrade, BCO1
Simas, NK1
Correa Ramos Leal, I1
Sangenito, LS1
Santos, ALSD1
de Oliveira, D1
Junges, A1
Cansian, RL1
Paroul, N1
Siu, J1
Klingler, L1
Hung, CT1
Jeong, SH1
Smith, S1
Tingle, MD1
Wagner Mackenzie, B1
Biswas, K1
Douglas, RG1
Oza, AM1
Lorusso, D1
Aghajanian, C1
Oaknin, A1
Dean, A1
Colombo, N1
Weberpals, JI1
Clamp, AR1
Scambia, G1
Leary, A1
Holloway, RW1
Gancedo, MA1
Fong, PC1
Goh, JC1
O'Malley, DM1
Armstrong, DK1
Banerjee, S1
García-Donas, J1
Swisher, EM1
Cella, D1
Meunier, J1
Goble, S1
Cameron, T1
Maloney, L1
Mörk, AC1
Bedel, J1
Ledermann, JA1
Coleman, RL1
Vlek, SL1
Burm, R1
Govers, TM1
Vleugels, MPH1
Tuynman, JB1
Mijatovic, V1
Leicht, AS1
Connor, J1
Conduit, N1
Vaquera, A1
Gómez, MA1
McKay, JA1
Church, AL1
Rubin, N1
Emory, TH1
Hoven, NF1
Kuehn-Hajder, JE1
Nelson, MT1
Ramanna, S1
Auerbach, EJ1
Moeller, S1
Bolan, PJ1
Fox, NP1
Leonard, M1
Sjerps, MJ1
Chang, EF1
Hyun, S1
Saejio, A1
Shanmugam, S1
Liu, X1
Sun, M1
Bai, Z1
Jaque-Fernandez, F1
Beaulant, A1
Berthier, C1
Monteiro, L1
Allard, B1
Casas, M1
Rieusset, J1
Jacquemond, V1
Góngora-García, OR1
Aca-Aca, G1
Baz-Rodríguez, SA1
Monte, A1
Maganaris, C1
Baltzopoulos, V1
Zamparo, P1
Wang, Z2
Hou, Y1
Cai, L1
Tu, YJ1
Tan, B1
Jiang, L1
Wu, ZH1
Yu, HJ1
Li, XQ1
Yang, AD1
Titze, IR1
Palaparthi, A1
Mau, T1
González, MA1
Goiri, F1
Barandika, JF1
García-Pérez, AL1
Jatt, LP1
Gandhi, MM1
Guo, R1
Sukhija-Cohen, A1
Bhattacharya, D1
Tseng, CH1
Chew, KW1
Onwumere, J1
Pia Tek, J1
Budnyak, T1
Budnyk, S1
Karim, Z1
Thersleff, T1
Kuśtrowski, P1
Mathew, AP1
Slabon, A1
Guo, M1
Zhao, T1
Xing, Z1
Qiu, Y1
Pan, K1
Li, Z2
Zhou, W2
Ghassemi Tabrizi, S1
Arbuznikov, AV1
Jiménez-Hoyos, CA1
Kaupp, M1
Lin, MH2
Bulman, DM1
Remucal, CK1
Chaplin, BP1
Laguerre, A1
George, LA1
Gall, ET1
Emerson, MS1
Wang, H5
Maginn, EJ1
Margulis, CJ1
Li, H2
Feng, W1
Kang, X2
Yan, S1
Chao, M1
Mo, S1
Sun, W1
Lu, Y1
Chen, C1
Stevens, DM1
Adiseshaiah, P1
Dasa, SSK1
Potter, TM1
Skoczen, SL1
Snapp, KS1
Cedrone, E1
Patel, N1
Busman-Sahay, K1
Rosen, EP1
Sykes, C1
Cottrell, M1
Dobrovolskaia, MA1
Estes, JD1
Kashuba, ADM1
Stern, ST1
Özütemiz, C1
Neil, EC1
Tanwar, M1
Rubin, NT1
Ozturk, K1
Cayci, Z1
Duscha, BD1
Kraus, WE1
Jones, WS1
Robbins, JL1
Piner, LW1
Huffman, KM1
Allen, JD1
Annex, BH1
Mehmood, T1
Ahmad, I1
Bibi, S1
Mustafa, B1
Ali, I1
Dahal, RH1
Chaudhary, DK1
Kim, DU1
Kim, J1
Yeter, HH1
Gonul, I1
Guz, G1
Helvaci, O1
Korucu, B1
Akcay, OF1
Derici, U1
Arinsoy, T1
Neffati, R1
Judeinstein, P1
Rault, J1
Xu, Y1
Chai, X1
Ren, T1
Yu, S2
Fu, Q2
Ye, J1
Ge, X1
Song, J1
Yang, H2
El-Baba, TJ1
Lutomski, CA1
Kantsadi, AL1
Malla, TR1
John, T1
Mikhailov, V1
Bolla, JR1
Schofield, CJ1
Zitzmann, N1
Vakonakis, I1
Robinson, CV1
Langham, MC1
Caporale, AS1
Wehrli, FW1
Parry, S1
Schwartz, N1
den Boer, RB1
Jones, KI1
Ash, S1
van Boxel, GI1
Gillies, RS1
O'Donnell, T1
Ruurda, JP1
Sgromo, B1
Silva, MA1
Maynard, ND1
Sivieri, EM1
Eichenwald, EC1
Rub, D1
Abbasi, S1
Krahnert, I1
Bolze, A1
Gibon, Y1
Fernie, AR1
Huang, L1
Wan, Y1
Dang, Z1
Yang, P1
Yang, Q1
Wu, S2
Lin, CC1
Hsu, CT1
Liu, W2
Huang, SC1
Kortz, U1
Mougharbel, AS1
Chen, TY1
Hu, CW1
Lee, JF1
Wang, CC1
Liao, YF1
Li, LJ1
Li, L1
Peng, S2
Stimming, U1
Hebbar Kannur, K1
Yaqub, TB1
Pupier, C1
Héau, C1
Cavaleiro, A1
Yamamoto, S1
Ono, A1
Matsui, J1
Hoshino, N1
Akutagawa, T1
Miyashita, T1
Mitsuishi, M1
Patel, SM1
Smith, TG1
Morton, M1
Stiers, KM1
Seravalli, J1
Mayclin, SJ1
Edwards, TE1
Tanner, JJ1
Becker, DF1
Butcher, TW1
Yang, JL1
Hartwig, JF1
Yu, MF1
Xia, ZZ1
Yao, JC1
Feng, Z1
Li, DH1
Liu, T1
Cheng, GJ1
He, DL1
Li, XH1
Huurman, R1
Schinkel, AFL1
de Jong, PL1
van Slegtenhorst, MA1
Hirsch, A1
Michels, M1
Kataja, A1
Tarvasmäki, T1
Lassus, J1
Sionis, A1
Mebazaa, A1
Pulkki, K1
Banaszewski, M1
Carubelli, V1
Hongisto, M1
Jankowska, E1
Jurkko, R1
Jäntti, T1
Kasztura, M1
Parissis, J1
Sabell, T1
Silva-Cardoso, J1
Spinar, J1
Tolppanen, H1
Harjola, VP1
Carsetti, A1
Damiani, E1
Casarotta, E1
Scorcella, C1
Domizi, R1
Gasparri, F1
Gabbanelli, V1
Pantanetti, S1
Carozza, R1
Adrario, E1
Donati, A1
Almada, E1
Pariani, A1
Rivabella Maknis, T1
Hidalgo, F1
Vena, R1
Favre, C1
Larocca, MC1
Lu, ZY1
Jiang, WD1
Wu, P1
Kuang, SY1
Tang, L1
Yang, J2
Zhou, XQ1
Feng, L1
Leal, M1
Zampini, IC1
Mercado, MI1
Moreno, MA1
Simirgiotis, MJ1
Bórquez, J1
Ponessa, G1
Isla, MI1
Saliu, IO1
Amoo, ZA1
Khan, MF1
Olaleye, MT1
Rema, V1
Akinmoladun, AC1
Khan, AU1
Rahman, AU1
Yuan, Q1
Ahmad, A1
Khan, ZUH1
Mahnashi, MH1
Alyami, BA1
Alqahtani, YS1
Ullah, S1
Wirman, AP1
Gao, M1
Deng, L1
Zhang, K1
Wang, M1
Xia, Z1
Gao, D1
Balkissou, AD1
Poka-Mayap, V1
Massongo, M1
Djenabou, A1
Endale-Mangamba, LM1
Olomo, EJ1
Boulleys-Nana, JR1
Diffo-Sonkoue, L1
Adidigue-Ndiome, R1
Alexandra, AJE1
Haman-Wabi, AB1
Adama, S1
Iddi-Faical, A1
Pefura-Yone, EW1
Zhao, Q1
Tong, W1
Ge, C1
Zhao, D1
Norbäck, D1
Li, B3
Zhao, Z2
Huang, C1
Zhang, X3
Qian, H1
Yang, X1
Sun, Y1
Sundell, J1
Deng, Q1
Kim, HJ1
Jeon, JW1
Hwang, SM1
Chu, KI1
Cha, YH1
Kwak, YD1
Choi, SD1
Aslam, M1
Kim, CG1
Zhou, J1
Yang, E1
Yang, W2
Dong, YH1
Chang, CH1
Wu, LC1
Hwang, JS1
Toh, S1
Franken, PR1
Woltersdorf, R1
Winiczenko, R1
Górnicki, K1
Kaleta, A1
Janaszek-Mańkowska, M1
Khan, ZA1
Singh, C1
Khan, T1
Ganguly, M1
Bradsher, C1
Goodwin, P1
Petty, JT1
Sandau, C1
Bove, DG1
Marsaa, K1
Bekkelund, CS1
Lindholm, MG1
Salazar, J1
Bermúdez, V1
Olivar, LC1
Torres, W1
Palmar, J1
Añez, R1
Ordoñez, MG1
Rivas, JR1
Martínez, MS1
Hernández, JD1
Graterol, M1
Rojas, J1
Mubarak, Z1
Humaira, A1
Gani, BA1
Muchlisin, ZA1
Gremillet, C1
Jakobsson, JG1
Gomila, A1
Shaw, E1
Carratalà, J1
Leibovici, L1
Tebé, C1
Wiegand, I1
Vallejo-Torres, L1
Vigo, JM1
Morris, S1
Stoddart, M1
Grier, S1
Vank, C1
Cuperus, N1
Van den Heuvel, L1
Eliakim-Raz, N1
Vuong, C1
MacGowan, A1
Addy, I1
Pujol, M1
Cobb, A1
Rieger, E1
Bell, J1
Mallik, S1
Szécsényi, Á1
Li, G1
Gascon, J1
Pidko, EA1
Zhang, GR1
Wolker, T1
Sandbeck, DJS1
Munoz, M1
Mayrhofer, KJJ1
Cherevko, S1
Etzold, BJM1
Lukashuk, L1
Yigit, N1
Rameshan, R1
Kolar, E1
Teschner, D1
Hävecker, M1
Knop-Gericke, A1
Schlögl, R1
Föttinger, K1
Rupprechter, G1
Franconieri, F1
Deshayes, S1
de Boysson, H1
Trad, S1
Martin Silva, N1
Terrier, B1
Bienvenu, B1
Galateau-Sallé, F1
Emile, JF1
Johnson, AC1
Aouba, A1
Vogt, TJ1
Gevensleben, H1
Dietrich, J1
Kristiansen, G1
Bootz, F1
Landsberg, J1
Goltz, D1
Dietrich, D1
Idorn, M1
Skadborg, SK1
Kellermann, L1
Halldórsdóttir, HR1
Holmen Olofsson, G1
Met, Ö1
Thor Straten, P1
Johnson, LE1
Brockstedt, D1
Leong, M1
Lauer, P1
Theisen, E1
Sauer, JD1
McNeel, DG1
Morandi, F1
Marimpietri, D1
Horenstein, AL1
Bolzoni, M1
Toscani, D1
Costa, F1
Castella, B1
Faini, AC1
Massaia, M1
Pistoia, V1
Giuliani, N1
Malavasi, F1
Qiu, J1
Yang, A1
Ma, Y1
Han, L1
Cheng, MA1
Farmer, E1
Hung, CF1
Wu, TC1
Modak, S1
Le Luduec, JB1
Cheung, IY1
Goldman, DA1
Ostrovnaya, I1
Doubrovina, E1
Basu, E1
Kushner, BH1
Kramer, K1
Roberts, SS1
O'Reilly, RJ1
Cheung, NV1
Hsu, KC1
Salgarello, T1
Giudiceandrea, A1
Calandriello, L1
Marangoni, D1
Colotto, A1
Caporossi, A1
Falsini, B1
Lefrançois, P1
Xie, P1
Tetzlaff, MT1
Moreau, L1
Watters, AK1
Netchiporouk, E1
Provost, N1
Gilbert, M1
Ni, X1
Sasseville, D1
Wheeler, DA1
Duvic, M1
Litvinov, IV1
O'Connor, BJ1
Fryda, NJ1
Ranglack, DH1
Grün, AL1
Emmerling, C1
Aumeeruddy-Elalfi, Z1
Ismaël, IS1
Hosenally, M1
Zengin, G1
Mahomoodally, MF1
Dotsenko, A1
Gusakov, A1
Rozhkova, A1
Sinitsyna, O1
Shashkov, I1
Sinitsyn, A1
Hong, CE1
Kim, JU1
Lee, JW1
Lee, SW1
Jo, IH1
Pandiyarajan, S1
Premasudha, P1
Kadirvelu, K1
Wang, B1
Luo, L1
Wang, D1
Ding, R1
Hong, J1
Caviezel, D1
Maissen, S1
Niess, JH1
Kiss, C1
Hruz, P1
Pockes, S1
Wifling, D1
Keller, M1
Buschauer, A1
Elz, S1
Santos, AF1
Ferreira, IP1
Pinheiro, CB1
Santos, VG1
Lopes, MTP1
Teixeira, LR1
Rocha, WR1
Rodrigues, GLS1
Beraldo, H1
Lohar, S1
Dhara, K1
Roy, P1
Sinha Babu, SP1
Chattopadhyay, P1
Sukwong, P1
Sunwoo, IY1
Lee, MJ1
Ra, CH1
Jeong, GT1
Kim, SK2
Huvinen, E1
Eriksson, JG1
Stach-Lempinen, B1
Tiitinen, A1
Koivusalo, SB1
Malhotra, M1
Suresh, S1
Garg, A1
Wei, L1
Jiang, Y2
Liu, S1
Rausch-Fan, X1
Liu, Z1
Marques, WL1
van der Woude, LN1
Luttik, MAH1
van den Broek, M1
Nijenhuis, JM1
Pronk, JT1
van Maris, AJA1
Mans, R1
Gombert, AK1
Xu, A1
Chen, W2
Zheng, R1
Han, Z1
Ji, L1
Shen, WQ1
Bao, LP1
Hu, SF1
Gao, XJ1
Xie, YP1
Gao, XF1
Huang, WH1
Lu, X1
Gostin, PF1
Addison, O1
Morrell, AP1
Cook, AJMC1
Liens, A1
Stoica, M1
Ignatyev, K1
Street, SR1
Wu, J1
Chiu, YL1
Davenport, AJ1
Qiu, Z1
Shu, J1
Tang, D1
Huang, K1
Wai, H1
Du, K1
Anesini, J1
Kim, WS1
Eastman, A1
Micalizio, GC1
Liang, JH1
Huo, XK1
Cheng, ZB1
Sun, CP1
Zhao, JC1
Kang, XH1
Zhang, TY1
Chen, ZJ1
Yang, TM1
Wu, YY1
Deng, XP1
Zhang, YX1
Salem, HF1
Kharshoum, RM1
Abou-Taleb, HA1
AbouTaleb, HA1
AbouElhassan, KM1
Ohata, C1
Ohyama, B1
Kuwahara, F1
Katayama, E1
Nakama, T1
Kobayashi, S1
Kashiwagi, T1
Kimura, J1
Lin, JD1
Liou, MJ1
Hsu, HL1
Leong, KK1
Chen, YT1
Wang, YR1
Hung, WS1
Lee, HY1
Tsai, HJ1
Tseng, CP1
Alten, B1
Yesiltepe, M1
Bayraktar, E1
Tas, ST1
Gocmen, AY1
Kursungoz, C1
Martinez, A1
Sara, Y1
Adams, E1
Van Schepdael, A1
Wang, Q1
Chung, CY1
Yang, G1
Chough, S1
Yin, B1
Bhattacharya, R1
Saeui, CT1
Yarema, KJ1
Betenbaugh, MJ1
Zhang, H1
Patik, JC1
Tucker, WJ1
Curtis, BM1
Nelson, MD1
Nasirian, A1
Park, S1
Brothers, RM1
Dohlmann, TL1
Hindsø, M1
Dela, F1
Helge, JW1
Larsen, S1
Gayani, B1
Dilhari, A1
Wijesinghe, GK1
Kumarage, S1
Abayaweera, G1
Samarakoon, SR1
Perera, IC1
Kottegoda, N1
Weerasekera, MM1
Nardi, MV1
Timpel, M1
Ligorio, G1
Zorn Morales, N1
Chiappini, A1
Toccoli, T1
Verucchi, R1
Ceccato, R1
Pasquali, L1
List-Kratochvil, EJW1
Quaranta, A1
Dirè, S1
Heo, K1
Jo, SH1
Shim, J1
Kang, DH1
Kim, JH1
Park, JH1
Akhtar, N1
Saha, A1
Kumar, V1
Pradhan, N1
Panda, S1
Morla, S1
Kumar, S1
Manna, D1
Xu, E1
Li, D1
Quan, J1
Xu, L1
Saslow, SA1
Um, W1
Pearce, CI1
Bowden, ME1
Engelhard, MH1
Lukens, WL1
Kim, DS1
Schweiger, MJ1
Kruger, AA1
Adair, LS1
Kuzawa, C1
McDade, T1
Carba, DB1
Borja, JB1
Liang, X2
Song, W1
Peele, ME1
Luo, HR1
Chen, ZY1
Fei, JJ1
Du, ZJ1
Yi, KJ1
Im, WT1
Kim, DW1
Ji, X1
Zhang, C1
Xu, Z1
Ding, Y1
Song, Q1
Lee, DW1
Lee, H1
Kwon, BO1
Khim, JS1
Yim, UH1
Park, H1
Park, B1
Choi, IG1
Kim, BS1
Kim, JJ1
Wang, JJ1
Li, YZ1
Sakai, M1
Yamaguchi, M1
Nagao, Y1
Kawachi, N1
Kikuchi, M1
Torikai, K1
Kamiya, T1
Takeda, S1
Watanabe, S1
Takahashi, T1
Arakawa, K1
Nakano, T1
Rufo, S1
Continentino, MA1
Nikolaou, V1
Plass, F1
Planchat, A1
Charisiadis, A1
Charalambidis, G1
Angaridis, PA1
Kahnt, A1
Odobel, F1
Coutsolelos, AG1
Fuentes, I1
García-Mendiola, T1
Sato, S1
Pita, M1
Nakamura, H1
Lorenzo, E1
Teixidor, F1
Marques, F1
Viñas, C1
Liu, F1
Qi, P1
Zhang, L1
Danda, D1
Iliyas, MM1
Chandy, SJ1
Chandra, C1
Mathew, AJ1
Munger, MA1
Gardner, SF1
Ateshkadi, A1
Rabetoy, GM1
Barri, YM1
Stoddard, GJ1
Cheung, AK1
MacDonald, TM2
Reginster, JY1
Littlejohn, TW1
Richard, D2
Lheritier, K2
Krammer, G2
Rebuli, R1
Krum, H1
Swergold, G1
Curtis, SP1
Kaur, A1
Smugar, SS1
Weir, MR1
Laine, L1
Brater, DC1
Cannon, CP1
Elliott, WJ1
Bavry, AA1
Khaliq, A1
Gong, Y1
Handberg, EM1
Cooper-Dehoff, RM1
Pepine, CJ1
Goswami, SK1
Jain, S1
Chudasama, H1
Santani, D1
Fournier, JP1
Sommet, A1
Bourrel, R1
Oustric, S1
Pathak, A1
Lapeyre-Mestre, M1
Montastruc, JL1
Peniston, JH1
Gold, MS1
Wieman, MS1
Alwine, LK1
Murray, B1
Carter, R1
Imrie, C1
O'Suilleabhain, C1
Freeman, ML1
Hermann, M2
Camici, G2
Fratton, A1
Hurlimann, D1
Tanner, FC1
Hellermann, JP1
Fiedler, M1
Thiery, J1
Neidhart, M1
Gay, RE1
Gay, S1
Lüscher, TF2
Ruschitzka, F2
Martinez, LL2
Oliveira, MA2
Miguel, AS2
Rastelli, VM3
Walber, J1
Cruz, MC1
Tostes, RC2
Carvalho, MH3
Nigro, D3
Fortes, ZB3
Izhar, M1
Alausa, T1
Folker, A1
Hung, E1
Bakris, GL1
Haffner, S1
Thürmann, PA1
Teekachunhatean, S1
Kunanusorn, P1
Rojanasthien, N1
Sananpanich, K1
Pojchamarnwiputh, S1
Lhieochaiphunt, S1
Pruksakorn, S1
Shaw, S1
Kiss, E1
Bühler, N1
Chenevard, R1
Gröne, HJ1
Cruz, JW1
Valat, JP1
Deray, G1
Héloire, F1
Tahvanainen, A1
Taurio, J1
Mäki-Jouppi, J1
Kööbi, P1
Mustonen, J1
Kähönen, M6
Sand, J1
Nordback, I1
Pörsti, I7
Gandhi, R1
Sharma, B1
Sood, J1
Rodrigues, SF1
Dossantos, RA1
de Oliveira, MA1
Nucci, Gd1
Tostes, Rde C1
Shibouta, Y1
Terashita, ZI1
Inada, Y1
Kato, K1
Nishikawa, K1
Reimann, IW1
Ratge, D1
Wisser, H1
Frölich, JC1
Richer, C1
Domergue, V1
Vincent, MP1
Giudicelli, JF1
Wu, X6
Mäkynen, H3
Korpela, R1
Hutri-Kähönen, N2
Tolvanen, JP4
Sallinen, K2
Koren, W1
Shahar, A1
Kalliovalkama, J2
Karjala, K1
Jolma, P1
Holm, P1
Arvola, P1
Riutta, A1
Mucha, I1
Solakivi, T1
Kainulainen, H1
Falcone, JC1
Meininger, GA1
Subramaniam, R1
Pandit, B1
Sadhasivam, S1
Sridevi, KB1
Kaul, HL1
Jick, SS1
Bhagat, K1
Gertz, BJ1
Krupa, D1
Bolognese, JA1
Sperling, RS1
Reicin, A1
Stokes, GS1
Brooks, PM1
Johnston, HJ1
Monaghan, JC1
Okoro, EO1
Kelly, D1
Takeuchi, K1
Abe, K1
Yasujima, M1
Sato, M1
Tanno, M1
Sato, K1
Yoshinaga, K1
Hovette, P1
Touze, JE1
Debonne, JM1
Delmarre, B1
Rogier, C1
Schmoor, P1
Aubry, P1
Koopmans, PP1
Thien, T1
Gribnau, FW1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A 4-week, Multicentre, Randomized, Double-blind, Double-dummy, Parallel Group Ambulatory Blood Pressure Monitoring Study to Investigate Whether Treatment With Lumiracoxib 100 mg Once Daily Results in an Improved 24-hour Blood Pressure Profile Compared to [NCT00267176]Phase 41,020 participants Interventional2005-11-30Completed
A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445]Phase 323,498 participants (Actual)Interventional2003-01-31Completed
Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)[NCT02111707]Phase 4534 participants (Actual)Interventional2014-04-30Completed
[NCT00121901]Phase 31,600 participants (Anticipated)Interventional2004-10-31Completed
Comparative Effectiveness Between Rectally Administered Indomethacin and Pancreatic Stenting in the Prevention of Post Endoscopic Retrograde Cholangio-panceaticography (ERCP) Pancreatitis: a Randomized Trial[NCT03713879]Phase 31,734 participants (Anticipated)Interventional2019-03-21Recruiting
Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) - Induced Pancreatitis Using Aggressive Lactated Ringer's Infusion and/or Rectal Indomethacin[NCT02641561]Phase 3192 participants (Actual)Interventional2014-10-31Completed
A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis[NCT02465138]Phase 40 participants (Actual)Interventional2023-11-30Withdrawn (stopped due to Lack of Funding)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Length of Stay (LOS) of Participants After ERCP if Medical Care is Sought as Assessed in Days

(NCT02641561)
Timeframe: 30 days after ERCP

Interventiondays (Mean)
A (NS+Placebo)2.3
B (NS+IND)2.2
C (LR+Placebo)1.9
D (LR+IND)4.3

The Number of Participants Who Undergo Surgery After ERCP, as Assessed by Surgical Operative Report

(NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants Who Were Readmitted After ERCP as Assessed by Medical Record and Patients Self-reporting

(NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)6
B (NS+IND)2
C (LR+Placebo)2
D (LR+IND)1

The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Either Elevated Amylase or Lipase 3 x Upper Limit of Normal

amylase or lipase (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Imaging Suggestive of Acute Pancreatitis

Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)1
C (LR+Placebo)0
D (LR+IND)1

The Number of Participants With Acute Respiratory Distress Syndrome (ARDS) After ERCP as Assessed by ARDSnet Criterion (Below)

bilateral opacities on chest imaging not explained by other lung pathology, respiratory failure not explained by heart failure or volume, and overload and a pulmonary arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio under 300, PaO2/FiO2 ratio is the partial pressure arterial oxygen and fraction of inspired oxygen (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)1
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Mortality After ERCP as Assessed by Medical Record Reporting

(NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)1
B (NS+IND)2
C (LR+Placebo)2
D (LR+IND)1

The Number of Participants With Multiple Organ Failure (MOF) After ERCP as Assessed by Elevated Creatinine Blood Test

creatinine > 1.5 milligrams/deciliter (mg/dL) (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)1
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Multiple Organ Failure (MOF) After ERCP as Assessed by Elevated International Normalized Ratio (INR)

INR > 1.5 (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Pancreatic Abscess After ERCP as Assessed by Abdominal Imaging Suggestive of Pancreatic Abscess

Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Pancreatic Pseudocyst After ERCP as Assessed by Abdominal Imaging Suggestive of Pseudocyst

Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)1

The Number of Participants With Perforation After ERCP as Assessed by Abdominal Imaging Suggestive of Perforation

Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Post-procedural Medical Care (ED Visit, Urgent Care, Hospitalization) as Assessed by Medical Record and Patients Self-reporting

(NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)6
B (NS+IND)2
C (LR+Placebo)2
D (LR+IND)1

The Number of Participants With Sepsis After ERCP as Assessed by Infectious Source Defined by Positive Microbiology Culture

positive blood culture (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

> 10% immature neutrophils (band forms). (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

Heart rate > 90 beats per minutes (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

PaCO2 < 4.3 kilopascal (kPa) (32 mmHg) (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

Respiratory rate > 20 breaths per minute (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

Temperature < 36°C(96.8°F) or > 38°C(100.4°F) (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)10
B (NS+IND)6
C (LR+Placebo)9
D (LR+IND)3

The Number of Participants With Systemic Inflammatory Response Syndrome (SIRS) After ERCP as Assessed by the SIRS Criterion (Below)

white blood cell (WBC) count < 4000 cells/mm³ (4 x 109 cells/L) (NCT02641561)
Timeframe: 30 days after ERCP

InterventionParticipants (Count of Participants)
A (NS+Placebo)0
B (NS+IND)0
C (LR+Placebo)0
D (LR+IND)0

Reviews

4 reviews available for diclofenac and Hypertension

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
    Current hypertension reports, 2010, Volume: 12, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Dic

2010
[Which drug interactions the general practitioner should know].
    Medizinische Klinik (Munich, Germany : 1983), 2004, Mar-15, Volume: 99, Issue:3

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diclofenac; Drug Interaction

2004
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas

2006

Trials

16 trials available for diclofenac and Hypertension

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
    Neural computing & applications, 2018, Volume: 30, Issue:6

    Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp

2018
    Neural computing & applications, 2018, Volume: 30, Issue:6

    Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp

2018
    Neural computing & applications, 2018, Volume: 30, Issue:6

    Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp

2018
    Neural computing & applications, 2018, Volume: 30, Issue:6

    Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp

2018
Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study.
    Pharmacotherapy, 2008, Volume: 28, Issue:7

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cross-Over Studies; Diclofenac; Doubl

2008
Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
    Journal of hypertension, 2008, Volume: 26, Issue:8

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Blood Pressure Monitoring, Ambulatory

2008
Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
    Journal of hypertension, 2009, Volume: 27, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Cyclooxygenase

2009
The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents.
    International journal of clinical practice, 2010, Volume: 64, Issue:6

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cyclooxygen

2010
Potential pharmacodynamic drug-drug interaction between concomitantly administered lisinopril and diclofenac sodium: a call for appropriate management in hypertensive osteoarthritic patients.
    Drug metabolism and drug interactions, 2011, Volume: 26, Issue:3

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Bloo

2011
Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities.
    Clinical interventions in aging, 2012, Volume: 7

    Topics: Administration, Cutaneous; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardio

2012
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos

2003
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.
    Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:3

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anti

2004
Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892].
    BMC complementary and alternative medicine, 2004, Dec-13, Volume: 4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dizziness; Double-Blind Method; Drugs, C

2004
Are prostaglandins involved in the antihypertensive effect of dihydralazine?
    Clinical science (London, England : 1979), 1981, Volume: 61 Suppl 7

    Topics: Adult; Diclofenac; Dihydralazine; Drug Therapy, Combination; Female; Humans; Hydralazine; Hypertensi

1981
Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics.
    East African medical journal, 2001, Volume: 78, Issue:10

    Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive

2001
The effects of sulindac and diclofenac in essential hypertension controlled by treatment with a beta blocker and/or diuretic.
    Clinical and experimental hypertension. Part A, Theory and practice, 1991, Volume: 13, Issue:6-7

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Creatinine; Diclo

1991
No adverse effect of non-steroidal anti-inflammatory drugs, sulindac and diclofenac sodium, on blood pressure control with a calcium antagonist, nifedipine, in elderly hypertensive patients.
    The Tohoku journal of experimental medicine, 1991, Volume: 165, Issue:3

    Topics: Aged; Blood Pressure; Diclofenac; Dinoprostone; Drug Therapy, Combination; Female; Humans; Hypertens

1991
The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide.
    European journal of clinical pharmacology, 1987, Volume: 31, Issue:5

    Topics: Adult; Aged; Aldosterone; Blood Pressure; Clinical Trials as Topic; Creatinine; Diclofenac; Drug The

1987

Other Studies

28 other studies available for diclofenac and Hypertension

ArticleYear
The effect of etoricoxib versus diclofenac on blood pressure in hypertensive patients.
    JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71(Suppl 9), Issue:12

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cyclooxygenase 2 Inhibitors; D

2021
Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
    British journal of clinical pharmacology, 2018, Volume: 84, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Cyclooxygenase 2 In

2018
Risk of renal dysfunction in an elderly patient with chronic heart failure.
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:10

    Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio

2016
How safe is Celecoxib for Asian-Indian patients with rheumatic diseases?
    International journal of rheumatic diseases, 2013, Volume: 16, Issue:1

    Topics: Adult; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Drug Substitution; Female; Humans; Hyperten

2013
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
    The American journal of medicine, 2011, Volume: 124, Issue:7

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec

2011
Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study.
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:11

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory

2012
Prevention of post-ERCP pancreatitis: pharmacologic solution or patient selection and pancreatic stents?
    Gastroenterology, 2003, Volume: 124, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac

2003
Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Circulation, 2003, Nov-11, Volume: 108, Issue:19

    Topics: Acetylcholine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cycloo

2003
Enalapril interferes with the effect of diclofenac on leucocyte-endothelium interaction in hypertensive rats.
    Journal of cardiovascular pharmacology, 2004, Volume: 43, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pr

2004
Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:2

    Topics: Animals; Blood Pressure; Blood Vessels; C-Reactive Protein; CD8-Positive T-Lymphocytes; Celecoxib; C

2005
Losartan attenuates the antimigratory effect of diclofenac in spontaneously hypertensive rats.
    Journal of cardiovascular pharmacology, 2005, Volume: 46, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Cell Adhe

2005
Increased wall tension in response to vasoconstrictors in isolated mesenteric arterial rings from patients with high blood pressure.
    Basic & clinical pharmacology & toxicology, 2006, Volume: 99, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Diclofenac; Female; Humans; Hypertension; In Vitro Techniques; Male;

2006
Severe anaphylaxis during general anaesthesia in a beta-blocked cardiac patient: considerations.
    Acta anaesthesiologica Scandinavica, 2008, Volume: 52, Issue:4

    Topics: Adrenergic beta-Antagonists; Anaphylaxis; Anesthesia, General; Anti-Inflammatory Agents; Anti-Inflam

2008
Amlodipine reduces the antimigratory effect of diclofenac in spontaneously hypertensive rats.
    Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:5

    Topics: Amlodipine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressur

2008
Renal effects of pinane-thromboxane A2 and indomethacin in saline volume-expanded spontaneously hypertensive rats.
    European journal of pharmacology, 1982, Nov-05, Volume: 85, Issue:1

    Topics: Animals; Bicyclic Monoterpenes; Blood Pressure; Diclofenac; Hypertension; Indomethacin; Kidney; Male

1982
Involvement of nitric oxide, but not prostaglandins, in the vascular sympathoinhibitory effects of losartan in the pithed spontaneously hypertensive rat.
    British journal of pharmacology, 1996, Volume: 117, Issue:2

    Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Cyclooxygenase Inhibitors; Decerebrate State;

1996
Whey mineral supplementation and arterial tone in mineralocorticoid-NaCl hypertension.
    Cardiovascular research, 1996, Volume: 32, Issue:6

    Topics: Acetylcholine; Animals; Cyclooxygenase Inhibitors; Desoxycorticosterone; Diclofenac; Hypertension; I

1996
Ramipril therapy improves arterial dilation in experimental hypertension.
    Cardiovascular research, 1997, Volume: 33, Issue:1

    Topics: Acetylcholine; Angiotensin-Converting Enzyme Inhibitors; Animals; Cyclooxygenase Inhibitors; Diclofe

1997
Xiphodynia masking acute myocardial infarction: a diagnostic cul-de-sac.
    The American journal of emergency medicine, 1998, Volume: 16, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chest Pain; Creatine Kinase; Diagnosis, Differential; Diclo

1998
Influence of gender on control of arterial tone in experimental hypertension.
    The American journal of physiology, 1998, Volume: 275, Issue:1

    Topics: Acetylcholine; Adenosine Diphosphate; Adrenergic beta-Agonists; Animals; Apamin; Blood Pressure; Cal

1998
Losartan and enalapril therapies enhance vasodilatation in the mesenteric artery of spontaneously hypertensive rats.
    European journal of pharmacology, 1999, Mar-05, Volume: 368, Issue:2-3

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diclofenac; Enalapril; Endothelium; E

1999
Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism.
    Cardiovascular research, 1999, Volume: 42, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cromakalim; Cyclooxygenase Inhibitors; Di

1999
Exercise enhances vasorelaxation in experimental obesity associated hypertension.
    Cardiovascular research, 1999, Volume: 43, Issue:4

    Topics: 6-Ketoprostaglandin F1 alpha; Acetylcholine; Analysis of Variance; Animals; Blood Glucose; Carotid A

1999
Endothelin mediates a component of the enhanced myogenic responsiveness of arterioles from hypertensive rats.
    Microcirculation (New York, N.Y. : 1994), 1999, Volume: 6, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arterioles; Culture Techniques; Diclofenac; Endoth

1999
Retroperitoneoscopic excision of phaeochromocytoma--haemodynamic events, complications and outcome.
    Anaesthesia and intensive care, 2000, Volume: 28, Issue:1

    Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adult; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ste

2000
The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam.
    Pharmacotherapy, 2000, Volume: 20, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cyclooxygenase 2; Cyclooxygenase 2 In

2000
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Current medical research and opinion, 2002, Volume: 18, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials, Phase II as Topic; Clinic

2002
[Cholestatic hepatitis and acute kidney insufficiency during treatment with diclofenac].
    Annales de gastroenterologie et d'hepatologie, 1989, Volume: 25, Issue:6

    Topics: Acute Kidney Injury; Aged; Chemical and Drug Induced Liver Injury; Cholestasis; Diclofenac; Female;

1989